Immune checkpoint inhibitors and the development of granulomatous reactions - 11/10/19
Abstract |
Immune checkpoint inhibitors (ICPIs) have emerged as a frontline treatment for a growing list of malignancies. Disruption of the negative regulatory immune checkpoints by ICPIs has been associated with many immune-related adverse events. Granulomatous reactions, such as sarcoidosis-like reactions, granulomatous panniculitis, granuloma annulare, and granulomatous dermatitis, are uncommon but increasingly recognized immune-related adverse events seen in patients treated with ICPIs. The frequency and significance of these eruptions, including whether they portend responsiveness to treatment, remain unclear. Additionally, understanding the role of immune checkpoint blockade in these reactions may provide mechanistic insight into the relevant signaling pathways involved in sarcoidosis and other granulomatous disorders.
Le texte complet de cet article est disponible en PDF.Key words : checkpoint inhibitors, CTLA4, granuloma annulare, granulomatous, granulomatous dermatitis, granulomatous panniculitis, immune-related adverse events, PD-1, sarcoidosis
Abbreviations used : CTLA4, GA, GD, GR, ICPI, irAE, PD-1, PD-L1, SLR, Th17 cell
Plan
Funding sources: None. |
|
Conflicts of interest: Dr Rosenbach attended a single-day advisory board for Merck which included discussion about checkpoint inhibitor reactions. The other authors declared no conflicts of interest. |
Vol 81 - N° 5
P. 1165-1175 - novembre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?